arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

KYNTRA BIO, INC.

KYNB
$7.24 ▲ +0.24 (+3.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bullish
auto_awesome

Analytical Summary

KYNTRA BIO, INC. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $29.3M
Dividend Yield
Revenue Growth -78.3%
Op. Margin None
ROIC -101.9%
FCF / Share $-1.19
Trailing P/E 0.2x
Price / Book
FCF Yield
Debt / Equity -2.50
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.44M
↓ -78.3%
Net Income Profit after all expenses
$183.45M
↑ +485.6%
Operating Margin Operating profit as % of sales
-190.7%
↑ +10.8%
FCF / Share Free cash flow per share
$-1.19
↑ +96.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
3
Financial Health
68
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters